EYEG - EyeGate Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.00
-0.20 (-2.78%)
As of 9:31AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close7.20
Open6.68
Bid0.00 x 900
Ask8.20 x 900
Day's Range6.53 - 7.20
52 Week Range2.25 - 12.89
Volume20,418
Avg. Volume131,723
Market Cap31.84M
Beta (5Y Monthly)2.63
PE Ratio (TTM)N/A
EPS (TTM)-2.34
Earnings DateFeb 28, 2019 - Mar 03, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est90.00
  • ACCESSWIRE

    EyeGate Pharma Completes Enrollment in Follow-on PE Pilot Study

    The study uses the Ocular Bandage Gel ("OBG") eye drop to treat patients with PE and is evaluating several different exploratory performance endpoints. Following data from this study, which is expected by the end of the first quarter of 2020, EyeGate plans to meet with the FDA to discuss the results and confirm the most ideal endpoint to use in the pivotal study. EyeGate's lead product, Ocular Bandage Gel ("OBG"), is based on a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique properties providing hydration and healing when applied to the ocular surface.

  • ACCESSWIRE

    EyeGate Announces Completion of $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

    EyeGate intends to use the net proceeds to obtain additional capital to support its operations, including for clinical trials, for working capital and for other general corporate purposes, which will include the pursuit of other research and development efforts and could also include the acquisition or in-license of other products, product candidates or technologies, though no such acquisition or in-license is current contemplated. EyeGate has not yet determined the amount of net proceeds to be used specifically for any of the foregoing purposes. The shares of common stock described above were offered and sold by EyeGate pursuant to an effective shelf registration statement on Form S-3 (file No. 333-231204), which was filed with the Securities and Exchange Commission (the "SEC") on May 3, 2019 and subsequently declared effective on May 13, 2019 (File No. 333-231204) (the "Registration Statement"), the base prospectus dated as of May 13, 2019 contained therein and a final prospectus supplement that EyeGate filed with the SEC on December 31, 2019 in connection with the sale of the shares of its common stock.

  • ACCESSWIRE

    EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

    EyeGate intends to use the net proceeds to obtain additional capital to support its operations, including for clinical trials, for working capital and for other general corporate purposes, which will include the pursuit of other research and development efforts and could also include the acquisition or in-license of other products, product candidates or technologies, though no such acquisition or in-license is current contemplated. The shares of common stock described above will be offered and sold by EyeGate pursuant to an effective shelf registration statement on Form S-3 (file No. 333-231204), which was filed with the Securities and Exchange Commission (the "SEC") on May 3, 2019 and subsequently declared effective on May 13, 2019 (File No. 333-231204) (the "Registration Statement"), and the base prospectus dated as of May 13, 2019 contained therein.

  • ACCESSWIRE

    EyeGate Pharma Receives $1.9 Million from Exercised Warrants

    The Company is currently evaluating several strategic options in order to determine the best path forward. Following the receipt of warrant exercise proceeds, the Company believes it will have sufficient cash to fund its planned operations through this evaluation process. In addition, the Company has received the full data package for this study and is now working on the De Novo application.

  • ACCESSWIRE

    EyeGate Pharma Announces Additional Positive Top-Line Data in PRK Pivotal Study

    As previously announced, the results of this pivotal study demonstrated statistically significant improvement in corneal re-epithelialization in patients treated with EyeGate's Ocular Bandage Gel ("OBG") eye drop versus the standard-of-care, a bandage contact lens ("BCL") post photorefractive keratectomy ("PRK") surgery. Additionally, OBG demonstrated a more rapid corneal wound closure over the standard-of-care as early as day two.

  • Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Fri., Nov. 22, 2019: TSLA, UBER, SPLK, EYEG, WKHS

    Benzinga Pro's Stocks To Watch For Friday Tesla (TSLA)  - Shares were down about 3% to under the $350 level following Thursday evening's  unveiling  of the company's new pickup, the Cybertruck.  Uber (UBER) ...

  • ACCESSWIRE

    EyeGate Pharma Hits Primary Endpoint in PRK Pivotal Study

    The results of this critical study demonstrated that EyeGate’s OBG eye drop provided a greater improvement in corneal re-epithelialization than those treated with the standard-of-care, a bandage contact lens. The statistical significance measurement was based on the number of subjects in each arm that achieved complete corneal defect closure three days post refractive surgery. At day 3, 80.2% of eyes receiving the OBG treatment regimen were completely healed compared with 67.0% for standard-of-care.

  • Zacks Small Cap Research

    EYEG: OBG-PRK Pivotal Data Upcoming, 2020 Launch? OBG-PE Pre-Pivotal Study Moving Quick, Pivotal in 2020?

    By Brian Marckx, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT OBG-PRK: Pivotal Data Upcoming, 2020 Launch Feasible OBG-PE: Pre-Pivotal Study Moving Quick, Pivotal in 2020? We continue to be encouraged by the recent rapid and consistent progress of both the OBG-PRK and OBG-PR programs. The quick pace the ongoing studies follows speediness in nailing down clinical site, trial design and

  • ACCESSWIRE

    EyeGate Pharma Reports Third Quarter 2019 Financial Results and Provides Business Update

    WALTHAM, MA / ACCESSWIRE / November 7, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the quarter ended September 30, 2019 and provided an update on recent corporate and operational activities. Stephen From, Chief Executive Officer of EyeGate, said, "We are on track to receive topline results for the corneal wound healing pivotal study before the end of 2019 and continue to enroll for the follow-on pilot study in patients with punctate epitheliopathies ("PE"). Completed enrollment of 250 patients for its corneal wound healing pivotal study in patients who have undergone photorefractive keratectomy ("PRK") surgery.

  • ACCESSWIRE

    EyeGate Pharma Completes Randomization in Pivotal Study

    WALTHAM, MA / ACCESSWIRE / October 9, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed randomization for its corneal wound repair pivotal study using the Ocular Bandage Gel ("OBG") eye drop. The study enrolled a total of 250 patients requiring corneal wound repair following photorefractive keratectomy ("PRK") surgery. The enrollment process included a formal screening to determine suitability for the procedure, followed by surgery and subsequent randomization into either the OBG or standard-of-care group.

  • ACCESSWIRE

    EyeGate Pharma Enrolls First Patient in Follow-on PE Pilot Study

    WALTHAM, MA / ACCESSWIRE / October 9, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has enrolled the first patient in its follow-on pilot study for punctate epitheliopathies ("PE"). The study will use the Ocular Bandage Gel ("OBG") eye drop to treat patients with PE to evaluate several different exploratory performance endpoints. "We are pleased to be underway with this clinical study, as we believe our unique OBG product will be the first approved eye drop in the U.S. for the treatment of PE," said Stephen From, CEO of EyeGate.

  • ACCESSWIRE

    EyeGate Enters Into Agreement for $1.9 Million Private Placement

    WALTHAM, MA / ACCESSWIRE / September 30, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG), ("EyeGate" or the "Company"), a clinical-stage company focused on developing products for treating disorders of the eye, today announced that it has entered into a securities purchase agreement in connection with a private placement (the "Private Placement") with an affiliate of Armistice Capital, LLC ("Armistice") for aggregate gross proceeds of approximately $1.9 million. Steven J. Boyd, a director of EyeGate, is the Chief Investment Officer of Armistice. The Private Placement is expected to close on or about October 2, 2019, subject to the satisfaction of customary closing conditions.

  • ACCESSWIRE

    EyeGate Pharma Regains Nasdaq Listing Compliance

    WALTHAM, MA / ACCESSWIRE / September 23, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that the Company has regained compliance with Nasdaq Listing Rule 5550 (a)(2), which concerns minimum bid price listing requirements. "We are pleased to be in full compliance with this listing standard and that the matter has been deemed closed by Nasdaq", said Stephen From, EyeGate's Chief Executive Officer. EyeGate's lead product, Ocular Bandage Gel ("OBG"), is based on a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique properties providing hydration and healing when applied to the ocular surface.

  • ACCESSWIRE

    EyeGate Pharma Reaches 75% Randomization of Patients in Pivotal Study

    WALTHAM, MA / ACCESSWIRE / September 16, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed randomization of over 75% of the patients required for its corneal wound repair pivotal study using the Ocular Bandage Gel (“OBG”) eye drop. The pivotal study will enroll up to 270 patients requiring corneal wound repair following photorefractive keratectomy (“PRK”) surgery.

  • ACCESSWIRE

    EyeGate Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference

    WALTHAM, MA / ACCESSWIRE / September 3, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it will be attending and presenting at the upcoming 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. The conference will be held September 8-10, 2019 at the Lotte New York Palace Hotel. Stephen From, Chief Executive Officer of EyeGate, will provide an overview of the business and its two ongoing clinical trials. EyeGate’s lead product, Ocular Bandage Gel (“OBG”), is based on a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique properties providing hydration and healing when applied to the ocular surface.

  • ACCESSWIRE

    EyeGate Pharma Announces Reverse Stock Split Effective August 30, 2019

    WALTHAM, MA / ACCESSWIRE / August 29, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today a reverse stock split of its shares of common stock at a ratio of 1-for-15. Upon the commencement of trading on August 30, 2019, the Company's common stock will begin trading on a post-split basis. The reverse stock split is being implemented primarily to bring the Company into compliance with the minimum bid price requirements for maintaining its listing on The Nasdaq Capital Market.

  • ACCESSWIRE

    EyeGate Pharma Reaches 50% Randomization of Patients in Pivotal Study

    WALTHAM, MA / ACCESSWIRE / August 26, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed randomization of over 50% of the patients required for its corneal wound repair pivotal study using the Ocular Bandage Gel (“OBG”) eye drop. The pivotal study will enroll up to 270 patients requiring corneal wound repair following photorefractive keratectomy (“PRK”) surgery. If approved, the surgery is scheduled for approximately 2 weeks post the screening visit, after which the patient is randomized into either the OBG or standard-of-care group.

  • ACCESSWIRE

    EyeGate Pharma Reports Second Quarter 2019 Financial Results and Provides Business Update

    WALTHAM, MA / ACCESSWIRE / August 8, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the quarter ended June 30, 2019 and provided an update on recent corporate and operational activities. Stephen From, Chief Executive Officer of EyeGate, said, “I am pleased with the clinical progress of our lead product, the Ocular Bandage Gel (“OBG”). In addition, we expect the follow-on PE pilot study to be underway in the near future.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Allakos (NASDAQ: ALLK ) shares were up 112.6% ...

  • Benzinga

    Eyegate Pharmaceuticals Receives FDA Approval To Begin PE Pilot Study

    Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) shares are trading higher after the company received FDA approval to initiate its follow-on pilot study for punctate epitheliopathies (PE). The study will use the Ocular Bandage Gel eye drop to treat patients with PE, which can be associated with dry eyes. "We are excited to get underway with another clinical study and very pleased with our continued cooperation and collaboration with the FDA," said CEO Stephen From.

  • ACCESSWIRE

    EyeGate Pharma Receives Approval from FDA to Initiate PE Pilot Study

    WALTHAM, MA / ACCESSWIRE / August 5, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received approval from the U.S. Food and Drug Administration (“FDA”) to initiate its follow-on pilot study for punctate epitheliopathies (“PE”). The study will use the Ocular Bandage Gel (“OBG”) eye drop to treat patients with PE, which can be associated with dry eye.

  • ACCESSWIRE

    EyeGate Pharma Announces Randomization of First 25% of Patients in Pivotal Study

    WALTHAM, MA / ACCESSWIRE / July 31, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed randomization of over 25% of the patients required for its corneal wound repair pivotal study using the Ocular Bandage Gel (“OBG”) eye drop. The pivotal study will enroll and randomize up to 270 patients requiring corneal wound repair following photorefractive keratectomy (“PRK”) surgery.

  • ACCESSWIRE

    EyeGate Files FDA Submission to Initiate PE Pilot Study

    WALTHAM, MA / ACCESSWIRE / July 9, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today it has filed a protocol with the FDA for a follow-on pilot study using the Ocular Bandage Gel ("OBG") eye drop to treat punctate epitheliopathies ("PE") which can be associated with dry eye. The FDA review process takes 30 days, at which point the FDA will allow the Company to initiate enrollment or will provide comments to be addressed. The objective of this study is to evaluate several different exploratory performance endpoints in PE patients.

  • ACCESSWIRE

    EyeGate Announces First Patient Enrolled in PRK Pivotal Study

    WALTHAM, MA / ACCESSWIRE / June 26, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company") announced today it has enrolled the first patient in its corneal wound repair pivotal study in patients having undergone photorefractive keratectomy ("PRK") surgery. Barbara Wirostko MD, Chief Medical Officer of EyeGate, said, "There is a significant need for an effective and accessible Hyaluronic Acid ("HA") eyedrop formulation in the U.S. that can help re-epithelialize corneal defects due to surgery, injuries, and diseases.